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Abstract
Background: Site‐1 Protease (S1P) is a Golgi‐resident protein required for the acti-
vation of regulatory proteins that drive key cellular functions, including, the unfolded 
protein response (UPR) and lipid and cholesterol biosynthesis. While disruptions in 
S1P function have been widely characterized in animal models, to date, the implica-
tions of disrupted S1P function in human disease states are not completely known.
Methods: The patient and both parents underwent whole exome and mitochondrial 
DNA sequencing, and Sanger sequencing was used to confirm the mutation. Western 
blotting and immunofluorescence studies were performed on either proband‐derived 
fibroblasts or on an established cell line to assess protein expression and cellular 
localization of the mutated S1P protein. Quantitative real‐time PCR and luciferase 
reporter assays were used to examine activation of S1P target pathways in the context 
of the S1P mutation.
Results: We describe a female patient with a de novo heterozygous missense muta-
tion in the transmembrane domain of S1P (p. Pro1003Ser). The patient presented to 
our neuromuscular clinic with episodic, activity‐induced, focal myoedema and my-
algias with hyperCKemia. Her clinical phenotype was complex and included gastro-
intestinal hypomotility, ocular migraines, and polycystic ovary syndrome. Molecular 
analysis using proband‐derived fibroblasts and cell lines harboring the Pro1003Ser 
mutation demonstrated increased activation of UPR and lipid and cholesterol regula-
tory pathways and localization of S1P Pro1003Ser in the Golgi.
Conclusion: These findings suggest a critical function for S1P in several human 
organ systems and implicate an important role for S1P in various human disease 
states.
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1 |  INTRODUCTION
Site‐1 Protease (S1P; also known as subtilisin/kexin‐iso-
zyme 1 or PCSK8) is a membrane‐bound serine protease 
required for the activation of key regulators of cellular 
functions, most notably, the unfolded protein response 
(UPR), lysosomal biogenesis, and lipid and cholesterol bio-
synthesis (Marschner, Kollmann, Schweizer, Braulke, & 
Pohl, 2011; Raggo et al., 2002; Sakai et al., 1998; Stirling 
& O’hare, 2006; Ye et al., 2000). Disruptions in these cel-
lular functions are implicated in several human diseases 
and restoring their normal function is a common thera-
peutic focus (Cohen, Horton, & Hobbs, 2011; Goldstein, 
Hazzard, Schrott, Bierman, & Motulsky, 1973; Hong, Kim, 
Kim, & Park, 2017; Hotamisligil, 2010). S1P is encoded 
by the MBTPS1 gene (OMIM accession number 603355) 
and exists as an inactive precursor in the endoplasmic retic-
ulum (ER) (Elagoz, Benjannet, Mammarbassi, Wickham, 
& Seidah, 2002; Espenshade, Cheng, Goldstein, & Brown, 
1999; Seidah et al., 1999). After a series of autocatalytic 
cleavage events, the mature S1P localizes to the Golgi 
where it can proteolytically cleave its substrates, the most 
well‐known being the sterol regulatory element‐binding 
protein family (SREBPs) of transcription factors, essential 
regulators of lipid and cholesterol homeostasis, and ATF6, 
a component of the UPR required to restore ER homeosta-
sis (Elagoz et al., 2002; Espenshade et al., 1999; Sakai et 
al., 1998; Seidah et al., 1999; Ye et al., 2000).
Many animal studies suggest an important role for S1P in 
developmental, physiologic, and pathogenic functions (Brandl 
et al., 2009; Hawkins et al., 2008; Hay et al., 2007; Kondo et 
al., 2018; Rutschmann et al., 2012; Uchida et al., 2016; Yang 
et al., 2001). These observations along with S1P's regulation 
of signaling pathways involved in insulin resistance, nonal-
coholic fatty liver disease, and persistent viral infection has 
made S1P the focus of pharmacological development efforts 
(Hawkins et al., 2008; Hay et al., 2007; Uchida et al., 2016). 
While these animal studies underscore an important role for 
S1P in health and disease, to date, the impact of S1P disrup-
tion on human health is not clearly understood.
Here, we describe a 24‐year old female patient with a novel 
heterozygous de novo mutation in MBTPS1 (NM_003791.3 
c.3007C>T) that corresponds to a mutation in the highly 
conserved transmembrane domain of S1P (NP_003782.1 p.
Pro1003Ser). The mutated MBTPS1 transcript is expressed 
at levels similar to the wild‐type transcript. The patient ex-
hibited a complex phenotype suggestive of disrupted me-
tabolism that includes muscle fatigue and hyperCKemia 
precipitated by moderate physical activity. Additional clini-
cal complications include ovarian cysts, small fiber neuropa-
thy, and chronic constipation. Our functional analysis of the 
mutant protein indicates Golgi localization of the protein and 
increased activation of its target pathways.
2 |  METHODS
2.1 | Editorial policies and ethical 
considerations
All procedures followed were in accordance with the 
ethical standards of the responsible committee on human 
experimentation (institutional and national) and with 
the Helsinki Declaration of 1975, as revised in 2000. 
Written informed consent was obtained from the patient 
and her parents for exome and mitochondrial DNA se-
quencing and the patient provided written informed con-
sent to participate in research studies to investigate the 
clinical significance of the genetic variant as approved 
by the Institutional Review Board (IRB) of Washington 
University in St. Louis.
2.2 | Whole exome and mitochondrial 
DNA sequencing
Exome sequencing was performed by GeneDx 
(Gaithersburg, MD) using Agilent SureSelect XT2 All 
Exon V4 Kit and Illumina HiSeq 2000 100 bp paired‐end 
reads. Sequence was aligned to the UCSC build hg19 ref-
erence sequence. Mean depth of coverage of known pro-
tein‐coding RefSeq genes was 89× with a quality threshold 
of 97.9%. For the MBTPS1 gene (gDNA NG_033017.1, 
cDNA NM_003791.3), 94.1% of the coding region was 
covered at a minimum of 10X by exome sequencing. 
GeneDx's XomeAnalyzer was used to evaluate sequence 
changes between the proband, parental samples, and refer-
ence. Sanger sequencing was used for confirmation of the 
reported mutation.
2.3 | Transcript characterization
Genomic DNA and RNA were extracted from patient and 
healthy donor fibroblasts using RNA‐Bee (Tel‐Test, Inc.) 
and cDNA was synthesized from RNA using SuperScript III 
(Invitrogen). To assess possible allele‐specific expression of 
the c.3007 mutant allele, sets of PCR primers were designed 
that would amplify a genomic DNA or cDNA region that in-
cludes the MBTPS1 c.3007C>T variant. The genomic DNA 
primers were located in adjacent introns, while the cDNA 
primers were located in adjacent exons, spanning two exon–
exon junctions. Both the genomic and cDNA‐derived PCR 
products were sequenced on an Applied Biosystems 3130xl 
capillary sequencer and the Sanger trace files were com-
pared with Applied Biosystems Sequence Analysis software. 
Illumina adaptors were ligated onto the ends of the patient 
and control cDNA‐derived PCR products and deep next‐gen-
eration sequencing was performed using an Illumina Miseq 
instrument (Illumina).
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2.4 | Cell culture
All cells were maintained at 37°C with 5% CO2. Primary 
skin fibroblasts were derived from patient and healthy donor 
skin biopsies under an approved IRB protocol at Washington 
University School of Medicine (protocol #: 201103019). 
Human fibroblasts were cultured in high‐glucose DMEM 
supplemented with 10% fetal bovine serum (FBS) and 1% 
penicillin‐streptomycin (PS). Patient and donor fibroblasts 
were used at matched passage numbers no greater than pas-
sage 10. The S1P‐deficient SRD‐12B cell line, a generous 
gift from Drs. Michael Brown and Joseph Goldstein of the 
University of Texas Southwestern Medical Center at Dallas 
and Dr. Peter J. Espenshade of the Johns Hopkins University 
School of Medicine, (Rawson, Cheng, Brown, & Goldstein, 
1998) was maintained in Medium B (DMEM/F12, 5% FBS, 
1% PS, 5 μg/ml cholesterol, 1 mmol/L sodium mevalonate, 
20  μmol/L sodium oleate). Medium A (DMEM/F12, 1% 
PS) was supplemented with 5% lipoprotein‐deficient serum 
(LPDS) where indicated.
2.5 | Cell growth assay
On Day 0, SRD‐12B cells were plated in 6  cm2 dishes at 
2  ×  105 in Medium B, transfected using Lipofectamine 
2000  (Invitrogen) with wild‐type S1P, S1P Pro1003Ser, or 
empty vector on Day 1, and shifted to Medium A with 5% 
LPDS on Day 2. Medium was changed every two days and 
on Day 7, cells were rinsed in PBS, fixed in ice‐cold metha-
nol at −20°C, and stained with 5% crystal violet.
2.6 | Luciferase reporter assay
On Day 0, SRD‐12B cells were plated in 12‐well plates at 
50% confluency in Medium B. On Day 1, wells were trans-
fected in quadruplicate using 3 μl FuGENE HD (Promega), 
50 μl Optimem Media (Gibco), 1.25 μg FAS‐Luc, 0.12 μg 
Renilla, and either 0.25 μg wild‐type S1P or S1P Pro1003Ser 
constructs per well. After 9–10 hr, cells were washed twice 
with 1× PBS and fed DMEM/F12 for 16 hr. Luciferase ac-
tivities were then measured using the Promega Dual‐Glo 
Luciferase Assay kit and the ratio between firefly and Renilla 
luciferase activities was determined.
2.7 | Immunofluorescence
Human skin fibroblasts were transfected using Lipofectamine 
2000 with either wild‐type S1P or S1P Pro1003Ser con-
structs. After 24  hr, cells were fixed in paraformaldehyde 
and incubated with anti‐FLAG, anti‐KDEL, and anti‐GM130 
antibodies followed by appropriate secondary antibodies. 
Cells were DAPI stained and visualized by fluorescence 
microscopy.
2.8 | Statistical analysis
Data are expressed as mean ± SEM. Student's t tests were 
used to determine significant differences. p < 0.05 was con-
sidered statistically significant. Additional methods can be 
found in Supplemental Material.
3 |  RESULTS
The proband presented to our neuromuscular clinic for eval-
uation of recurrent episodes of hyperCKemia with muscle 
fatigue, swelling, and myoedema. During her first reported 
episode, she presented with elevated levels of creatine ki-
nase (8,517 U/L), aspartate aminotransferase (212 U/L), and 
alanine aminotransferase (145  U/L), despite not exercising 
for over a week prior to the incident. Her interictal serum 
creatine kinase levels were normal. Subsequent episodes of 
hyperCKemia developed within hours to days of moderate 
exercise. After the first episode she developed persistent 
muscle fatigue that was consistently exacerbated by heavy 
activity and exercise, but no objective motor deficits were 
evident on exam. Prior to her first episode of hyperCKemia, 
the patient had been highly athletic in high school and col-
lege, having competed in track and volleyball. As an infant, 
the patient had normal motor development and was born at 
full term. She sustained a broken kneecap and hip from a vol-
leyball injury at age 20 but had no major musculoskeletal 
injuries or impairments. Additional clinical complications in-
cluded small fiber and autonomic/enteric neuropathy compli-
cated by chronic constipation, gastroparesis, gastrointestinal 
hypomotility and chronic nausea and vomiting, unexplained 
fevers with leukocytosis, ocular migraines, pelvic inflamma-
tory disease, and polycystic ovary syndrome based on the 
Rotterdam criteria (Rotterdam ESHRE/ASRM‐Sponsored 
PCOS Consensus Workshop Group, 2004).
Muscle histology revealed normal skeletal muscle struc-
ture, lipid content, fiber type distribution, and mitochon-
drial respiratory chain function (Figure S1a–d). Electron 
microscopy showed the patient's skeletal muscle had subtle 
disorganization of ultrastructure consisting of subsarcolem-
mal collections of mitochondria with scattered fat globules 
(Figure S1e) and mildly abnormal size and shape (Figure 
S1f); however, mitochondrial enzymatic activities were 
normal.
Whole exome and mitochondrial DNA sequencing of the 
proband and her parents revealed a heterozygous de novo 
missense mutation in exon 23 of the MBTPS1 (NM_003791.3 
c.3007C>T) gene that corresponded to a single amino 
acid substitution in the transmembrane domain of S1P 
(NP_003782.1 p.Pro1003Ser) (Figure 1a). Proline 1003 is 
highly conserved across both vertebrate and invertebrate spe-
cies (Figure 1b). The MBTPS1 c.3007C>T mutation was not 
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F I G U R E  1  Genetic and functional analysis of S1P Pro1003Ser. (a) Schematic of S1P protein with the Pro1003Ser mutation and S1P protein 
domains indicated, TM, transmembrane domain. (b) Multispecies alignment of S1P amino acid sequences demonstrating the mutated proline 
1003 residue is conserved (shown in bold). (c) mRNA expression levels of the MBTPS1 transcript in cultured control‐ and patient‐derived skin 
fibroblasts. n = 3. (d) Sanger sequencing trace files of patient genomic DNA (top) and cDNA (bottom)‐derived PCR products at the MBTPS1 
c.3007C>T locus. Intron–exon boundary (genomic) and exon–exon junction (cDNA) are indicated. Arrows denote the variant location. (e) Western 
blot of whole‐cell lysates (60μg) from SRD‐12B cells transiently transfected with mock, WT S1P, or S1P Pro1003Ser plasmids after 24 hr. S1P‐A, 
B, and C forms are indicated. Blots were probed with S1P and α‐tubulin (loading control) antibodies. n = 3. (f) SRD‐12B cells were transfected as 
in (e) and grown either in medium supplemented with lipids and cholesterol (left column) or in lipid‐ and cholesterol‐free medium (right column) 
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identified in the ~6,500 individuals of European and African 
American ancestry in the NHLBI Exome Sequencing Project. 
This variant was not found among healthy controls based on 
ExAc and GnomAD; however, a mutation in the same codon 
(p.Pro1003His) was found in 1/108,864 European alleles by 
GnomAD. Substitution of a hydrophobic proline with a polar 
serine at residue 1003 within the transmembrane domain of 
S1P was predicted to be deleterious by PolyPhen‐2 (HDIV 
score 0.993; probably damaging), Align GVGD (score Class 
65; most likely to interfere with function), and MutationTaster 
(p = 0.999; disease causing), but not by SIFT (score 0.19; 
tolerated) (Adzhubei et al., 2010; Kumar, Henikoff, & Ng, 
2009; Mathe et al., 2006; Schwarz, Cooper, Schuelke, & 
Seelow, 2014; Tavtigian et al., 2006). MBTPS1 transcript lev-
els in proband‐derived skin fibroblasts were similar to levels 
measured in control fibroblasts isolated from an individual 
without an S1P mutation (Figure 1c). Comparison of the 
Sanger sequencing trace files of the patient's genomic and 
cDNA‐derived PCR products at the MBTPS1 c.3007C>T 
locus showed approximately equal expression of the wild‐
type and mutant transcripts (Figure 1d). Deep next genera-
tion sequencing of the patient cDNA‐derived PCR products 
confirmed this observation, with 7216x coverage and approx-
imately equal allele balance (3,452 wild‐type alleles [47.8%] 
and 3,764 mutant alleles [52.2%]).
While disruption of S1P in mice decreases total plasma 
triglyceride and cholesterol levels (Yang et al., 2001), the pa-
tient's total plasma triglyceride and cholesterol levels were 
normal (Table S1) and her BMI was 20.7 kg/m2.
S1P must undergo multiple autocatalytic processing 
events in the ER before it can localize to the Golgi as an 
active mature protease (designated as C: 96 kDa estimated) 
(Espenshade et al., 1999; Ramos da Palma, Cendron, Seidah, 
Pasquato, & Kunz, 2015; Sakai et al., 1998). The ER‐res-
ident S1P precursors exist as a proprotein (designated as 
A: 115 kDa estimated) and an intermediate cleaved protein 
(designated as B: 102  kDa estimated) (Espenshade et al., 
1999; Ramos da Palma et al., 2015). To examine whether the 
variant MBTPS1 allele produced these three S1P forms, we 
transfected a Chinese hamster ovary cell line that lacks S1P, 
SRD‐12B, (Rawson et al., 1998) with plasmids encoding 
either human wild‐type (WT) S1P or S1P Pro1003Ser with 
a C‐terminal FLAG tag and visualized proteins via Western 
blot analysis. S1P Pro1003Ser‐transfected cells expressed all 
three forms of S1P as did WT S1P‐transfected cells (Figure 
1e).
Because S1P is required for SREBP‐dependent lipid and 
cholesterol biosynthesis, SRD‐12B cells, which lack S1P, are 
lipid and cholesterol auxotrophs and must be supplemented 
with lipids and cholesterol to survive (Rawson et al., 1998). 
To test the functionality of S1P Pro1003Ser, we performed a 
cell complementation assay with SRD‐12B cells transfected 
with human S1P Pro1003Ser or WT S1P and grew cells in 
the absence of lipids and cholesterol. While mock transfected 
SRD‐12B cells failed to grow under these conditions, as re-
ported previously (Rawson et al., 1998), SRD‐12B cells that 
expressed S1P Pro1003Ser grew in the absence of supple-
mented lipids and cholesterol similar to WT S1P‐expressing 
cells (Figure 1f).
To further examine the functionality of S1P Pro1003Ser, 
we tested the mutant's ability to activate its substrate path-
ways, SREBP and ATF6, using S1P Pro1003Ser patient‐de-
rived fibroblasts and control fibroblasts from an individual 
without an S1P mutation. Treatment of sterol‐depleted cells 
with the HMG‐CoA reductase inhibitor mevastatin (com-
pactin) promotes transcription of SREBP1a and 2 target 
genes (Brown, Faust, Goldstein, Kaneko, & Endo, 1978; 
Shimomura, Shimano, Horton, Goldstein, & Brown, 1997). 
We examined whether S1P Pro1003Ser patient‐derived fi-
broblasts respond to mevastatin treatment. S1P Pro1003Ser 
fibroblasts showed a dosage‐dependent increase in the ex-
pression of SREBP1 and 2 target genes that was higher than 
the expression levels of treated control fibroblasts (Figure 
2a). Even in the absence of mevastatin, expression levels of 
SREBP1 and 2 target genes were elevated in S1P Pro1003Ser 
fibroblasts compared to control fibroblasts (Figure 2a). We 
next tested whether S1P Pro1003Ser could activate ATF6, a 
transcription factor required to restore ER homeostasis during 
ER stress, by treating fibroblasts with tunicamycin to induce 
ER stress. S1P Pro1003Ser patient fibroblasts treated with 
tunicamycin had higher expression levels of spliced XBP‐1 
and the ATF6 target genes Grp78 and CHOP than control fi-
broblasts (Figure 2b). To determine whether S1P Pro1003Ser 
could directly activate SREBPs, we performed a luciferase 
reporter assay using an SREBP1‐response fatty acid synthase 
luciferase promoter construct. SRD‐12B cells expressing S1P 
Pro1003Ser exhibited higher levels of SREBP1‐dependent 
promoter activity than cells expressing WT S1P (Figure 2c).
The intracellular localization of mature S1P and its 
substrates to the Golgi is an important regulatory mecha-
nism that governs S1P function (DeBose‐Boyd et al., 1999; 
Marschner et al., 2011; Nohturfft, DeBose‐Boyd, Scheek, 
Goldstein, & Brown, 1999; Raggo et al., 2002; Sakai et al., 
1998; Shen, Chen, Hendershot, & Prywes, 2002; Stirling & 
O’hare, 2006; Ye et al., 2000). To begin to understand the 
mechanism behind the enhanced activity of S1P Pro1003Ser, 
we investigated whether S1P Pro1003Ser localization was 
altered in the patient's fibroblasts. Control and patient fibro-
blasts were transfected with either FLAG‐tagged human WT 
S1P or S1P Pro1003Ser, respectively, and double‐labeled 
with anti‐FLAG and antibodies against KDEL‐bearing pro-
teins (ER marker) and GM130 (Golgi marker) (Figure 2d). 
Similar to WT S1P, S1P Pro1003Ser localized to both the 
ER and the Golgi. This result was also observed when per-
formed in SRD‐12B cells transfected with WT S1P and S1P 
Pro1003Ser (Figure S3).
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4 |  DISCUSSION
In conclusion, we describe a patient with a de novo het-
erozygous variant in the gene MBTPS1 that produces a 
missense mutation in the transmembrane domain of S1P. 
Deep next generation sequencing showed that the mutant 
MBTPS1 transcript is expressed at levels similar to the 
wild‐type transcript in patient‐derived skin fibroblasts. The 
patient presented with a complex phenotype that included 
episodic hyperCKemia, focal myoedema, ocular migraines, 
and polycystic ovary syndrome. To date, associations be-
tween these clinical manifestations and S1P have not been 
described.
F I G U R E  2  S1P Pro1003Ser has enhanced activity and accumulates in the Golgi. mRNA expression levels in cultured control‐ and patient‐
derived skin fibroblasts of (a) SREBP1 and 2 target genes after 4 hr of treatment with the indicated concentrations of mevastatin and (b) UPR and 
ATF6 target genes following treatment with 1 µg/ml of tunicamycin for 4, 8, and 12 hr. (c) SRD‐12B cells transiently transfected with FAS‐Luc, 
Renilla, and WT S1P or S1P Pro1003Ser plasmids as indicated, after 10 hr, cells were treated with DMEM/F12 for 16 hr. Luciferase activities were 
measured and the ratio between firefly and Renilla luciferase activities was determined. (d) Immunofluorescence of S1P, ER marker KDEL, and 
Golgi marker GM130 in S1P Pro1003Ser patient and control fibroblasts. Cells were transfected with FLAG‐tagged WT S1P or S1P Pro1003Ser as 
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Our functional analysis showed the MBTPS1 variant pro-
duces a stable S1P Pro1003Ser protease that is able to com-
plement lipid and cholesterol biosynthetic capacities in cells 
that lack S1P and is abundant in both the ER and the Golgi. 
S1P Pro1003Ser exhibited enhanced activation of SREBP and 
UPR pathways compared to WT S1P, suggesting this mutant 
protein has an altered function, possibly a gain‐of‐function.
Reports have shown S1P can exist as multiple shed ecto-
domain species (Elagoz et al., 2002; Kim et al., 2018). While 
S1P Pro1003Ser produced the unprocessed precursor, an 
intermediate cleaved product, and the mature protease, we 
were unable to detect shed ectodomain species. This may be 
due to differences in culture conditions—indeed it has been 
shown that production of some shed S1P species requires 
specific conditions (e.g., increased Caspase‐2 expression, 
mouse models of nonalcoholic steatohepatitis) (Kim et al., 
2018) and/or due to differences in methodology (Elagoz et 
al. visualized shed S1P most abundantly in culture media via 
radiolabeling coupled with immunoprecipitation, while we 
performed standard Western blots of whole‐cell lysates).
S1P functions in concert with Site‐2 Protease (S2P) to 
activate substrates (Espenshade & Hughes, 2007). Loss‐of‐
function S2P mutations are well documented as contributors 
to human disease including skeletal dysplasia (Aten et al., 
2010; Bornholdt et al., 2013; Haghighi et al., 2013; Lindert et 
al., 2016; Naiki et al., 2012; Nakayama et al., 2011; Oeffner 
et al., 2009; Zhang et al., 2016). A recent study reported a 
case of human skeletal dysplasia in a pediatric patient with 
an S1P deficiency, resulting in disrupted ER stress, but re-
tained lipid homeostasis (Kondo et al., 2018). Based on our 
thorough clinical analysis, such S2P‐ and S1P‐associated 
syndromes were not present in the proband, most likely due 
to the loss‐of‐function nature of those previously identified 
mutations.
The S1P Pro1003Ser patient phenotype is complex and 
includes conditions that effect several organs including skel-
etal muscle and the ovary. These observations suggest that 
S1P may play a critical role in the functions of these organs in 
ways that are not yet understood, either via well‐known S1P 
substrates or yet to be identified substrates. Our observations 
underscore the importance of S1P in human physiology and 
shed light on a potential role for S1P in a diverse array of 
human disorders and organ systems.
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